Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co OCF Margin

The Operating Cash Flow Margin of Shanghai Fudan Forward S&T Co (600624.SS) as of Oct 29, 2026 is -6.42 %. In the previous year, Operating Cash Flow Margin was -2.24 % — a change of 187.03% (lower).

OCF Margin

-6.42 %

YoY

187.03%

Last updated:

Operating Cash Flow Margin of Shanghai Fudan Forward S&T Co is 2025 -6.42 % . Operating Cash Flow Margin of Shanghai Fudan Forward S&T Co was 2024 -2.24 % . It decreases by 187.03% lower compared to the previous year.

The Shanghai Fudan Forward S&T Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
12.54 CNY
Jan 1, 2019
1.33 CNY
Jan 1, 2020
6.28 CNY
Jan 1, 2021
4.38 CNY
Jan 1, 2022
3.57 CNY
Jan 1, 2023
1.03 CNY
Jan 1, 2024
-2.24 CNY
Jan 1, 2025
-6.42 CNY
The Shanghai Fudan Forward S&T Co OCF Margin history
YEAROCF MarginYoY
-6.42 %+187.03%
-2.24 %-316.22%
1.03 %-70.99%
3.57 %-18.50%
4.38 %-30.28%
6.28 %+371.27%
1.33 %-89.38%
12.54 %-4.36%
13.11 %-438.35%
-3.88 %-139.91%
9.71 %+173.62%
3.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

Operating Cash Flow Margin of Shanghai Fudan Forward S&T Co is -6.42 % in 2025.

Operating Cash Flow Margin of Shanghai Fudan Forward S&T Co changed from -2.24 % to -6.42 %, representing a 187.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Shanghai Fudan Forward S&T Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Shanghai Fudan Forward S&T Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Shanghai Fudan Forward S&T Co